Sarepta Therapeutics, Inc. (SRPT) Stock
NSQ · SRPT
20.11
Fundamentals
Market cap
$2.12B
Price / Earnings ratio
-16.0x
Price / Sales ratio
1.1x
Price / Book ratio
1.4x
Return on assets
0.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
SectorHealthcare
IndustryBiotechnology
Employees835
CEODr. Michael E. Severino M.D.
IPO DateJun 3, 1997
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ian Michael Estepan | President & COO | 1976 |
| Mr. Ryan H. Wong | Executive VP & CFO | 1979 |
| Ms. Cristin L. Rothfuss J.D. | Executive VP, General Counsel & Company Secretary | 1968 |
| Mr. Douglas S. Ingram Esq., J.D. | Advisor | 1963 |
| Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations | 1978 |
| Dr. Michael E. Severino M.D. | CEO & Director | 1966 |
| Rachael Potter Ph.D. | Chief Scientific Officer | — |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations | — |
| Ms. Alison Nasisi | Executive VP & Chief People Officer | — |
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer | — |
Fundamentals
Valuation
Market cap$2.12B
Price-to-sales ratio1.11
Price-to-book value1.43
Price-earnings ratio-16.00
Return on Equity5.00%
Return on Sales0.01%
Return on Assets0.02%
PEG ratio159.25
Earnings Per Share
Earnings Per Share$-1.46
Income Statement
Average volume3,100,685
EBITDA$82.73M
1 year high (52w)$25.32
1 year low (52w)$14.68
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



